1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc.

KPTI
Karyopharm Therapeutics Inc.US flagNASDAQ Global Select
0.35
USD
-0.04
- -
7.85MMarket Cap

Total Valuation

Karyopharm Therapeutics Inc. carries a market capitalization of 7.85M, placing it among publicly traded companies globally. Its enterprise value stands at 412.67M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap7.85M
Enterprise Value412.67M

Share Statistics

Karyopharm Therapeutics Inc. currently has 22.68M shares outstanding.

Shares Outstanding22.68M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

The price-to-sales ratio is 1.29, and the price-to-book ratio stands at -0.67.

PE RatioN/A
PS Ratio1.29
PB Ratio-0.67
P/TBV Ratio-0.67
P/FCF Ratio-3.00
P/OCF Ratio-2.90

Enterprise Valuation

EV / Sales2.81
EV / EBITDAN/A
EV / EBITN/A
EV / FCFN/A

Financial Position

Karyopharm Therapeutics Inc. maintains a current ratio of 0.79, meaning it holds 0.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -77.59, indicating conservative leverage, while an interest coverage ratio of -1.67 demonstrates limited ability to service its debt obligations.

Current Ratio0.79
Quick Ratio0.71
Debt / Equity-77.59
Debt / EBITDA-3.12
Interest Coverage-1.67

Financial Efficiency

Return on Equity (ROE)N/A
Return on Assets (ROA)-207.90
Return on Invested Capital (ROIC)N/A
Return on Capital Employed (ROCE)N/A
Revenue Per EmployeeN/A
Employee CountN/A
Inventory Turnover1.34

Taxes

Income Tax-32,000.00
Effective Tax RateN/A

Stock Price Statistics

Karyopharm Therapeutics Inc.'s stock has declined approximately -94.65224% over the past 52 weeks. The 50-day moving average sits at 1.47, while the 200-day moving average is 6.36.

Beta (5Y)N/A
52-Week Price Change-94.65224%
50-Day Moving Average1.47
200-Day Moving Average6.36
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, Karyopharm Therapeutics Inc. generated 146.62M in revenue and converted that into -224.74M in net income, yielding earnings per share of -11.21. EBITDA reached -82.20M, while operating income came in at -82.35M.

Revenue146.62M
Gross Profit140.59M
Operating Income-82.35M
Pretax Income-224.77M
Net Income-224.74M
EBITDA-82.20M
EBIT-82.35M
Earnings Per Share (EPS)-11.21

Balance Sheet

Karyopharm Therapeutics Inc. holds 65.11M in cash and equivalents against 256.19M in total debt, resulting in a net debt position of 194.96M. Total book value stands at -330.17M, with working capital of -27.85M providing operational flexibility.

Cash & Cash Equivalents65.11M
Total Debt256.19M
Net Debt194.96M
Equity (Book Value)-330.17M
Book Value Per Share-14.56
Working Capital-27.85M

Cash Flow

Karyopharm Therapeutics Inc. produced -65.35M in operating cash flow over the past twelve months.

Operating Cash Flow-65.35M
Capital ExpendituresN/A
Free Cash Flow-65.35M
FCF Per Share-3.37

Margins

Karyopharm Therapeutics Inc. operates with a gross margin of 95.89, reflecting its pricing power and cost economics. The operating margin of -56.17 and net profit margin of -153.28 provide insight into operational efficiency.

Gross Margin95.89
Operating Margin-56.17
Pretax Margin-153.30
Profit Margin-153.28
EBITDA Margin-56.06

Dividends & Yields

Dividend Per ShareN/A
Dividend YieldN/A
Payout RatioN/A
Shareholder Yield-35.47
FCF Yield-33.35

Stock Splits

Karyopharm Therapeutics Inc.'s most recent stock split took place on February 26, 2025 with a 15:1 split ratio.

Last Split Date2/26/2025
Split Ratio15:1

Scores

Karyopharm Therapeutics Inc. posts an Altman Z-Score of -24.38, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score-24.38